High-throughput quantitation method for amodiaquine and desethylamodiaquine in plasma using supported liquid extraction technology
Amodiaquine is a drug used for treatment of malaria and is often used in combination with artesunate in areas where malaria parasites are still susceptible to amodiaquine. Liquid chromatography tandem-mass spectrometry was used to quantify amodiaquine and its active metabolite, desethylamodiaquine,...
| প্রধান লেখক: | , , |
|---|---|
| বিন্যাস: | Journal article |
| ভাষা: | English |
| প্রকাশিত: |
Elsevier
2021
|
| _version_ | 1826309747881541632 |
|---|---|
| author | Kaewkhao, K Tarning, J Blessborn, D |
| author_facet | Kaewkhao, K Tarning, J Blessborn, D |
| author_sort | Kaewkhao, K |
| collection | OXFORD |
| description | Amodiaquine is a drug used for treatment of malaria and is often used in combination with artesunate in areas where malaria parasites are still susceptible to amodiaquine. Liquid chromatography tandem-mass spectrometry was used to quantify amodiaquine and its active metabolite, desethylamodiaquine, in plasma samples. A low sample volume of 100 µl, and high-throughput extraction technique using a supported liquid extraction (SLE<sup>+</sup>) technique on an automated liquid handler platform for faster sample processing are some of the advantages of this method. Separation of amodiaquine from desethylamodiaquine was achieved using a reversed phase Zorbax SB-CN 50 mm × 4.6 mm, I.D. 3.5 µm column with acetonitrile and 20 mM ammonium formate with 1% formic acid pH ~ 2.6 (15–85, v/v) as mobile phase. The absolute recoveries of amodiaquine and desethylamodiaquine were 66% to 76%, and their isotope label internal standard were in the range of 73% to 85%. Validation results of the developed method demonstrated intra-batch and inter-batch precisions within the acceptance criteria range of ± 15.0%. There were no matrix or carry-over effects observed. The lower limit of quantification was 1.08 ng/ml for amodiaquine and 1.41 ng/ml for desethylamodiaquine. The method showed robust and accurate performance with high sensitivity. Thus, the validated method was successfully implemented and applied in the evaluation of a clinical trial where participants received artemether–lumefantrine plus amodiaquine twice daily for three days (amodiaquine dose of 10 mg base/kg/day). |
| first_indexed | 2024-03-07T07:40:20Z |
| format | Journal article |
| id | oxford-uuid:07d01ff8-82f0-4159-ab3d-3977ff5edde6 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:40:20Z |
| publishDate | 2021 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:07d01ff8-82f0-4159-ab3d-3977ff5edde62023-04-21T10:41:51ZHigh-throughput quantitation method for amodiaquine and desethylamodiaquine in plasma using supported liquid extraction technologyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:07d01ff8-82f0-4159-ab3d-3977ff5edde6EnglishSymplectic ElementsElsevier2021Kaewkhao, KTarning, JBlessborn, DAmodiaquine is a drug used for treatment of malaria and is often used in combination with artesunate in areas where malaria parasites are still susceptible to amodiaquine. Liquid chromatography tandem-mass spectrometry was used to quantify amodiaquine and its active metabolite, desethylamodiaquine, in plasma samples. A low sample volume of 100 µl, and high-throughput extraction technique using a supported liquid extraction (SLE<sup>+</sup>) technique on an automated liquid handler platform for faster sample processing are some of the advantages of this method. Separation of amodiaquine from desethylamodiaquine was achieved using a reversed phase Zorbax SB-CN 50 mm × 4.6 mm, I.D. 3.5 µm column with acetonitrile and 20 mM ammonium formate with 1% formic acid pH ~ 2.6 (15–85, v/v) as mobile phase. The absolute recoveries of amodiaquine and desethylamodiaquine were 66% to 76%, and their isotope label internal standard were in the range of 73% to 85%. Validation results of the developed method demonstrated intra-batch and inter-batch precisions within the acceptance criteria range of ± 15.0%. There were no matrix or carry-over effects observed. The lower limit of quantification was 1.08 ng/ml for amodiaquine and 1.41 ng/ml for desethylamodiaquine. The method showed robust and accurate performance with high sensitivity. Thus, the validated method was successfully implemented and applied in the evaluation of a clinical trial where participants received artemether–lumefantrine plus amodiaquine twice daily for three days (amodiaquine dose of 10 mg base/kg/day). |
| spellingShingle | Kaewkhao, K Tarning, J Blessborn, D High-throughput quantitation method for amodiaquine and desethylamodiaquine in plasma using supported liquid extraction technology |
| title | High-throughput quantitation method for amodiaquine and desethylamodiaquine in plasma using supported liquid extraction technology |
| title_full | High-throughput quantitation method for amodiaquine and desethylamodiaquine in plasma using supported liquid extraction technology |
| title_fullStr | High-throughput quantitation method for amodiaquine and desethylamodiaquine in plasma using supported liquid extraction technology |
| title_full_unstemmed | High-throughput quantitation method for amodiaquine and desethylamodiaquine in plasma using supported liquid extraction technology |
| title_short | High-throughput quantitation method for amodiaquine and desethylamodiaquine in plasma using supported liquid extraction technology |
| title_sort | high throughput quantitation method for amodiaquine and desethylamodiaquine in plasma using supported liquid extraction technology |
| work_keys_str_mv | AT kaewkhaok highthroughputquantitationmethodforamodiaquineanddesethylamodiaquineinplasmausingsupportedliquidextractiontechnology AT tarningj highthroughputquantitationmethodforamodiaquineanddesethylamodiaquineinplasmausingsupportedliquidextractiontechnology AT blessbornd highthroughputquantitationmethodforamodiaquineanddesethylamodiaquineinplasmausingsupportedliquidextractiontechnology |